Skip to main content

Articles

Page 1 of 60

  1. Malignant brain tumors rank among the most challenging type of malignancies to manage. The current treatment protocol commonly entails surgery followed by radiotherapy and/or chemotherapy, however, the median ...

    Authors: Zoufang Huang, Saikat Dewanjee, Pratik Chakraborty, Niraj Kumar Jha, Abhijit Dey, Moumita Gangopadhyay, Xuan-Yu Chen, Jian Wang and Saurabh Kumar Jha
    Citation: Molecular Cancer 2023 22:22
  2. Excessive extracellular matrix deposition and increased stiffness are typical features of solid tumors such as hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC). These conditions creat...

    Authors: Zihan Yang, Li Zhou, Tongxu Si, Siyuan Chen, Chengxi Liu, Kelvin Kaki Ng, Zesheng Wang, Zhiji Chen, Chan Qiu, Guopan Liu, Qingliang Wang, Xiaoyu Zhou, Liang Zhang, Zhongping Yao, Song He, Mengsu Yang…
    Citation: Molecular Cancer 2023 22:21
  3. In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach to fight cancers. This approach consists of genetically engineered immune cells expressi...

    Authors: Karama Makni Maalej, Maysaloun Merhi, Varghese P. Inchakalody, Sarra Mestiri, Majid Alam, Cristina Maccalli, Honar Cherif, Shahab Uddin, Martin Steinhoff, Francesco M. Marincola and Said Dermime
    Citation: Molecular Cancer 2023 22:20
  4. Colorectal cancer liver metastases (CRCLM) are associated with a poor prognosis, reflected by a five-year survival rate of 14%. Anti-angiogenic therapy through anti-VEGF antibody administration is one of the l...

    Authors: Johannes Robert Fleischer, Alexandra Maria Schmitt, Gwendolyn Haas, Xingbo Xu, Elisabeth Maria Zeisberg, Hanibal Bohnenberger, Stefan Küffer, Laure-Anne Teuwen, Philipp Johannes Karras, Tim Beißbarth, Annalen Bleckmann, Mélanie Planque, Sarah-Maria Fendt, Peter Vermeulen, Michael Ghadimi, Joanna Kalucka…
    Citation: Molecular Cancer 2023 22:17
  5. hsa_circ_0001727 (circZKSCAN1) has been reported to be a tumor-associated circRNA by sponging microRNAs. Intriguingly, we found that circZKSCAN1 encoded a secretory peptide (circZKSaa) in the liver. The presen...

    Authors: Runjie Song, Shuoqian Ma, Jiajia Xu, Xin Ren, Peilan Guo, Huijiao Liu, Peng Li, Fan Yin, Mei Liu, Qiang Wang, Lei Yu, Jiali Liu, Binwei Duan, Nafis A. Rahman, Sławomir Wołczyński, Guangming Li…
    Citation: Molecular Cancer 2023 22:16
  6. Despite advances in early detection and therapies, cancer is still one of the most common causes of death worldwide. Since each tumor is unique, there is a need to implement personalized care and develop robus...

    Authors: Pavel Stejskal, Hani Goodarzi, Josef Srovnal, Marián Hajdúch, Laura J. van ’t Veer and Mark Jesus M. Magbanua
    Citation: Molecular Cancer 2023 22:15
  7. The acquisition of genetic abnormalities engendering oncogene dysregulation underpins cancer development. Certain proto-oncogenes possess several dysregulation mechanisms, yet how each mechanism impacts clinic...

    Authors: Charlotte Smith, Aurore Touzart, Mathieu Simonin, Christine Tran-Quang, Guillaume Hypolite, Mehdi Latiri, Guillaume P. Andrieu, Estelle Balducci, Marie-Émilie Dourthe, Ashish Goyal, Françoise Huguet, Arnaud Petit, Norbert Ifrah, André Baruchel, Hervé Dombret, Elizabeth Macintyre…
    Citation: Molecular Cancer 2023 22:12
  8. Skin cancer has emerged as the fifth most commonly reported cancer in the world, causing a burden on global health and the economy. The enormously rising environmental changes, industrialization, and genetic m...

    Authors: Leli Zeng, B. H. Jaswanth Gowda, Mohammed Gulzar Ahmed, Mohammed A. S. Abourehab, Zhe-Sheng Chen, Changhua Zhang, Jia Li and Prashant Kesharwani
    Citation: Molecular Cancer 2023 22:10
  9. Pancreatic cancer (PC) is a fatal disease that has a poor 5-year survival rate. The poor prognosis can be attributed to both troublesome detections at the initial stage, which makes the majority of the treatme...

    Authors: Zhe Liu, Neha Parveen, Urushi Rehman, Aisha Aziz, Afsana Sheikh, Mohammed A. S. Abourehab, Wei Guo, Junhao Huang, Zhenning Wang and Prashant Kesharwani
    Citation: Molecular Cancer 2023 22:8
  10. Gastric cancer (GC) is one of the most common tumors worldwide and the leading cause of tumor-related mortality. Endoscopy and serological tumor marker testing are currently the main methods of GC screening, a...

    Authors: Shuo Ma, Meiling Zhou, Yanhua Xu, Xinliang Gu, Mingyuan Zou, Gulinaizhaer Abudushalamu, Yuming Yao, Xiaobo Fan and Guoqiu Wu
    Citation: Molecular Cancer 2023 22:7
  11. Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is characterized by invasive growth, rapid metastasis and chemoresistance. Trastuzumab is an effective treatment for HER2+ breast cancer;...

    Authors: Fei Xing, Hongli Gao, Guanglei Chen, Lisha Sun, Jiayi Sun, Xinbo Qiao, Jinqi Xue and Caigang Liu
    Citation: Molecular Cancer 2023 22:6
  12. Accumulated evidence highlights the significance of the crosstalk between epigenetic and epitranscriptomic mechanisms, notably 5-methylcytosine (5mC) and N6-methyladenosine (m6A). Herein, we conducted a widesprea...

    Authors: Yu Tian, Haijuan Xiao, Yanhui Yang, Pingping Zhang, Jiahui Yuan, Wei Zhang, Lijie Chen, Yibao Fan, Jinze Zhang, Huan Cheng, Tingwei Deng, Lin Yang, Weiwei Wang, Guoyong Chen, Peiqin Wang, Peng Gong…
    Citation: Molecular Cancer 2023 22:5
  13. Metastatic colonization is one of the critical steps in tumor metastasis. A pre-metastatic niche is required for metastatic colonization and is determined by tumor-stroma interactions, yet the mechanistic unde...

    Authors: Yulan Mo, Leanne L. Leung, Celia S. L. Mak, Xueyu Wang, Wai-Sun Chan, Lynn M. N. Hui, Hermit W. M. Tang, Michelle K. Y. Siu, Rakesh Sharma, Dakang Xu, Stephen K. W. Tsui, Hextan Y. S. Ngan, Mingo M. H. Yung, Karen K. L. Chan and David W. Chan
    Citation: Molecular Cancer 2023 22:4
  14. This study aimed to validate whether infusion of GD2-specific fourth-generation safety-designed chimeric antigen receptor (4SCAR)-T cells is safe and whether CAR-T cells exert anti-glioblastoma (GBM) activity.

    Authors: Zhuohao Liu, Jiayi Zhou, Xinzhi Yang, Yuchen Liu, Chang Zou, Wen Lv, Cheng Chen, Kenneth King-yip Cheng, Tao Chen, Lung-Ji Chang, Dinglan Wu and Jie Mao
    Citation: Molecular Cancer 2023 22:3
  15. According to current guidelines, more than 70% of patients with invasive submucosal colorectal cancer (T1 CRC) undergo a radical operation with lymph node dissection, even though only ~ 10% have lymph node met...

    Authors: Katsuki Miyazaki, Yuma Wada, Keisuke Okuno, Tatsuro Murano, Yuji Morine, Tetsuya Ikemoto, Yu Saito, Hiroaki Ikematsu, Yusuke Kinugasa, Mitsuo Shimada and Ajay Goel
    Citation: Molecular Cancer 2023 22:2
  16. Small cell lung cancer (SCLC) is an aggressive lung cancer subtype that is associated with high recurrence and poor prognosis. Due to lack of potential drug targets, SCLC patients have few therapeutic options....

    Authors: Parvez Khan, Jawed Akhtar Siddiqui, Prakash G. Kshirsagar, Ramakanth Chirravuri Venkata, Shailendra Kumar Maurya, Tamara Mirzapoiazova, Naveenkumar Perumal, Sanjib Chaudhary, Ranjana Kumari Kanchan, Mahek Fatima, Md Arafat Khan, Asad Ur Rehman, Imayavaramban Lakshmanan, Sidharth Mahapatra, Geoffrey A. Talmon, Prakash Kulkarni…
    Citation: Molecular Cancer 2023 22:1
  17. Lung cancer is the most prevalent form of cancer and has a high mortality rate, making it a global public health concern. The N6-methyladenosine (m6A) modification is a highly dynamic and reversible process that ...

    Authors: Jin Wang, Lirong Tan, Xueting Yu, Xiyuan Cao, Beibei Jia, Rui Chen and Jianxiang Li
    Citation: Molecular Cancer 2022 21:229
  18. Breast cancer metastasis to the bone can be exacerbated by osteoporosis, is associated with poor long-term survival, and has limited therapeutic options. Sclerostin (SOST) is an endogenous inhibitor of bone fo...

    Authors: Lisha Sun, Yixiao Zhang, Guanglei Chen, Yaoting Ji, Qingtian Ma, Xinbo Qiao, Sijin Wu, Lin Zhou, Jiawen Bu, Xudong Zhu, Xiaoying Zhang, Xiaofan Jiang, Chao Liu, Xinnan Li, Yang Liu, Yongliang Yang…
    Citation: Molecular Cancer 2022 21:228
  19. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-017-0586-y.

    Authors: Jia-Xing Zhang, Yi Xu, Ying Gao, Cui Chen, Zhou-San Zheng, Miao Yun, Hui-Wen Weng, Dan Xie and Sheng Ye
    Citation: Molecular Cancer 2022 21:227
  20. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive T-cell malignancy characterized by genotypically-defined and phenotypically divergent cell populations, governed by adaptive landscapes. Clonal expa...

    Authors: Tommaso Colangelo, Patrizio Panelli, Francesco Mazzarelli, Francesco Tamiro, Valentina Melocchi, Elisabetta De Santis, Roberto Cuttano, Orazio Palumbo, Giovanni Rossi, Fabrizio Bianchi and Vincenzo Giambra
    Citation: Molecular Cancer 2022 21:226
  21. Cancer divergence has many facets other than being considered a genetic term. It is a tremendous challenge to understand the metastasis and therapy response in cancer biology; however, it postulates the opport...

    Authors: Palanisamy Nallasamy, Rama Krishna Nimmakayala, Seema Parte, Abhirup C. Are, Surinder K. Batra and Moorthy P. Ponnusamy
    Citation: Molecular Cancer 2022 21:225
  22. Recent studies have identified that circular RNAs (circRNAs) have an important role in cancer via their well-recognized sponge effect on miRNAs, which regulates a large variety of cancer-related genes. However...

    Authors: Yanping Liang, Junjie Cen, Yong Huang, Yong Fang, Yunfei Wang, Guannan Shu, Yihui Pan, Kangbo Huang, Jiaqi Dong, Mi Zhou, Yi Xu, Junhang Luo, Min Liu and Jiaxing Zhang
    Citation: Molecular Cancer 2022 21:224

    The Correction to this article has been published in Molecular Cancer 2023 22:14

  23. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/1476-4598-12-147.

    Authors: Sarita Saraswati, Shakti Kumar and Abdulqader A. Alhaider
    Citation: Molecular Cancer 2022 21:223
  24. Cancer drug resistance represents the main obstacle in cancer treatment. Drug-resistant cancers exhibit complex molecular mechanisms to hit back therapy under pharmacological pressure. As a reversible epigenet...

    Authors: Zaoqu Liu, Haijiao Zou, Qin Dang, Hui Xu, Long Liu, Yuyuan Zhang, Jinxiang Lv, Huanyun Li, Zhaokai Zhou and Xinwei Han
    Citation: Molecular Cancer 2022 21:220
  25. Adoptive cell therapy (ACT) using tumor infiltrating lymphocytes (TIL) is being studied in multiple tumor types. However, little is known about clonal cell expansion in vitro and persistence of the ACT product...

    Authors: Rihao Qu, Yuval Kluger, Junchen Yang, Jun Zhao, David A. Hafler, Diane S. Krause, Alexey Bersenev, Marcus Bosenberg, Michael Hurwitz, Liliana Lucca and Harriet M. Kluger
    Citation: Molecular Cancer 2022 21:219
  26. Esophageal squamous cell carcinoma (ESCC) is a common gastrointestinal malignant tumor, while the molecular mechanisms have not been fully elucidated. Multiple circular RNAs have been reported to involve in th...

    Authors: Lina Gu, Yang Sang, Xixi Nan, Yang Zheng, Fei Liu, Lingjiao Meng, Meixiang Sang and Baoen Shan
    Citation: Molecular Cancer 2022 21:217

    The Correction to this article has been published in Molecular Cancer 2023 22:19

  27. At present, there is no validated marker to identify the subpopulation of patients with advanced gastric cancer (AGC) who might benefit from neoadjuvant chemotherapy (NACT). In view of this clinical challenge,...

    Authors: Ting Guo, Xiao-Huan Tang, Xiang-Yu Gao, Yuan Zhou, Bo Jin, Zi-Qian Deng, Ying Hu, Xiao-Fang Xing, Zi-Yu Li and Jia-Fu Ji
    Citation: Molecular Cancer 2022 21:216
  28. Autoimmune disorders, including Systemic Lupus Erythematosus (SLE), are associated with increased incidence of hematological malignancies. The matricellular protein osteopontin (OPN) has been linked to SLE pat...

    Authors: Celeste Rizzello, Valeria Cancila, Sabina Sangaletti, Laura Botti, Chiara Ratti, Matteo Milani, Matteo Dugo, Francesco Bertoni, Claudio Tripodo, Claudia Chiodoni and Mario P. Colombo
    Citation: Molecular Cancer 2022 21:215
  29. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/1476-4598-13-69.

    Authors: Barbara Nuvoli, Sabrina Germoni, Carlotta Morosetti, Raffaela Santoro, Giancarlo Cortese, Serena Masi, Iole Cordone and Rossella Galati
    Citation: Molecular Cancer 2022 21:214
  30. Inactivation of the Hippo pathway promotes Yap nuclear translocation, enabling execution of a transcriptional program that induces tissue growth. Genetic lesions of Hippo intermediates only identify a minority...

    Authors: Maria E. R. Garcia-Rendueles, Gnana Krishnamoorthy, Mahesh Saqcena, Adrian Acuña-Ruiz, Giovanna Revilla, Elisa de Stanchina, Jeffrey A. Knauf, Rona Lester, Bin Xu, Ronald A. Ghossein and James A. Fagin
    Citation: Molecular Cancer 2022 21:213
  31. Non-small cell lung cancer (NSCLC) patients with primary tumors and liver metastases have substantially reduced survival. Since mesenchymal-epithelial transition factor (MET) plays a significant role in the mo...

    Authors: Yige Sun, Jie Yang, Yingbo Li, Jing Luo, Jiemei Sun, Daoshuang Li, Yuchen Wang, Kai Wang, Lili Yang, Lina Wu and Xilin Sun
    Citation: Molecular Cancer 2022 21:212
  32. The quality and quantity of tumor neoantigens derived from tumor mutations determines the fate of the immune response in cancer. Frameshift mutations elicit better tumor neoantigens, especially when they are n...

    Authors: Daniel Meraviglia-Crivelli, Helena Villanueva, Angelina Zheleva, María Villalba-Esparza, Beatriz Moreno, Ashwathi Puravankara Menon, Alfonso Calvo, Javier Cebollero, Martin Barainka, Igor Ruiz de los Mozos, Carlos Huesa-Berral and Fernando Pastor
    Citation: Molecular Cancer 2022 21:211
  33. Long noncoding RNAs (lncRNAs) have driven research focused on their effects as oncogenes or tumor suppressors involved in carcinogenesis. However, the functions and mechanisms of most lncRNAs in colorectal can...

    Authors: Xue Wang, Han Cheng, Jing Zhao, Jiuming Li, Ying Chen, Kaisa Cui, Lu Tian, Jia Zhang, Chaoqun Li, Shengbai Sun, Yuyang Feng, Surui Yao, Zehua Bian, Shenglin Huang, Bojian Fei and Zhaohui Huang
    Citation: Molecular Cancer 2022 21:210
  34. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s12943-018-0845-6.

    Authors: Fengting Huang, Wenying Chen, Juanfei Peng, Yuanhua Li, Yanyan Zhuang, Zhe Zhu, Chunkui Shao, Wanling Yang, Herui Yao and Shineng Zhang
    Citation: Molecular Cancer 2022 21:209
  35. Tumors are comprised of both cancer cells and surrounding stromal components. As an essential part of the tumor microenvironment, the tumor stroma is highly dynamic, heterogeneous and commonly tumor-type speci...

    Authors: Maosen Xu, Tao Zhang, Ruolan Xia, Yuquan Wei and Xiawei Wei
    Citation: Molecular Cancer 2022 21:208
  36. Exosomes are well-known key mediators of intercellular communication and contribute to various physiological and pathological processes. Their biogenesis involves four key steps, including cargo sorting, MVB f...

    Authors: Qing-Fang Han, Wen-Jia Li, Kai-Shun Hu, Jie Gao, Wen-Long Zhai, Jing-Hua Yang and Shui-Jun Zhang
    Citation: Molecular Cancer 2022 21:207
  37. Natural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic activity, have recently attracted attention as potential anticancer therapeutics. While NK cells mediate encouraging respon...

    Authors: Le Tong, Carlos Jiménez-Cortegana, Apple H.M. Tay, Stina Wickström, Lorenzo Galluzzi and Andreas Lundqvist
    Citation: Molecular Cancer 2022 21:206
  38. Brain cancer is regarded among the deadliest forms of cancer worldwide. The distinct tumor microenvironment and inherent characteristics of brain tumor cells virtually render them resistant to the majority of ...

    Authors: Xuchen Qi, Saurabh Kumar Jha, Niraj Kumar Jha, Saikat Dewanjee, Abhijit Dey, Rahul Deka, Pingal Pritam, Kritika Ramgopal, Weiting Liu and Kaijian Hou
    Citation: Molecular Cancer 2022 21:204

Annual Journal Metrics